

HPHCURRENT EVENTS**Harvard Pilgrim Regional Network Meeting: Manchester NH Kickoff Event**

Harvard Pilgrim is pleased to announce our new network engagement series — and we're excited to invite our New Hampshire providers and administrative staff to our first event in Manchester on Dec. 5.

Because we're invested in improving your experience with us and keeping you and your office staff well informed, we will be hosting a series of forums to share useful information — news and updates, product and policy information, and overviews of online resources and tools. Just as importantly, we welcome this invaluable opportunity to hear your firsthand feedback on what works best when doing business with us.

Sign up for our first event

Harvard Pilgrim will be hosting network forums at different locations across our New England markets, and the first event details are as follows:

Date: Dec. 5, 2018

Time: 8:30 a.m. to 11:30 a.m.

Location: Executive Court Banquet Facility

Address: 1199 South Mammoth Road, Manchester, NH

Schedule:

- **8:30 to 9:15 a.m.** – Continental breakfast and networking
- **9:15 to 11:30 a.m.** – Presentation

If you would like to attend, please register in advance by submitting the requested information on the [event RSVP page](#).

Let's network together!

Harvard Pilgrim's exceptional network is our most valued asset, supporting our mission by delivering high-quality care to our members. And we want to be the health plan that is easiest for you to do business with. Please join us at these forums so that we can work together to accomplish that goal.

For additional details, please contact your [Provider Relations Consultant](#) and look to future issues of *Network Matters* for information about upcoming events in other states. ◆

CLINICIAN CORNER

Prior Authorization for Cervical Spine Procedures

Harvard Pilgrim is expanding our existing musculoskeletal (MSK) prior authorization program with National Imaging Associates, Inc. (NIA) to include non-emergent inpatient and outpatient cervical spine surgeries for commercial and Medicare Advantage members. Effective for dates of service beginning Jan. 1, 2019, prior authorization is required for the following cervical spine surgeries and their associated allowable billed groupings:

- Cervical anterior decompression with fusion — single (22551) and multiple levels (22552)
- Cervical posterior decompression with fusion — single (22600) and multiple levels (22595)
- Cervical anterior decompression without fusion (63075)
- Cervical posterior decompression without fusion (63045)

Please refer to [NIA's clinical guidelines](#) and the [Utilization Review Matrix for Interventional Pain Management and Musculoskeletal Surgery](#) for complete coding information.

Requesting Authorization and Submitting Claims

Ordering physicians may request authorization via the NIA website (www.RadMD.com) or by phone at 800-642-7543. NIA will begin accepting authorization requests on Dec. 18, 2018. Providers can check on the status of their authorization requests easily through www.RadMD.com (log in and select the “My Exams Requests” tab).

Please continue to send claims directly to Harvard Pilgrim as you do today (for more information on claims submission, see the [Billing and Reimbursement section of Harvard Pilgrim's commercial Provider Manual](#) or the [Claims section of our StrideSM \(HMO\) Medicare Advantage Provider Manual](#)).

To ensure appropriate reimbursement, it is important that the rendering surgeon/facility confirms that authorization has been obtained prior to performing the procedure, as Harvard Pilgrim will deny payment for non-emergent cervical spine

surgeries performed without prior authorization. Members cannot be balance billed for such procedures.

Resources to assist you

For more information on this change, please refer to the following provider education materials:

- [MSK Program Quick Reference Guide](#)
- [MSK FAQs for Ordering Physicians](#)

[Utilization Review Matrix](#) for Interventional Pain Management and Musculoskeletal Surgery (including complete coding and allowable billed grouping information)◆

Medicare Advantage: Cardiac Prior Authorization Program

For dates of services beginning Jan. 1, 2019, Harvard Pilgrim will require prior authorization for Medicare Advantage members for the following non-emergent cardiac diagnostic tests and interventional procedures through National Imaging Associates, Inc. (NIA):

- Cardiac Resynchronization Therapy (CRT)
- Implantable Cardioverter Defibrillator (ICD)
- Pacemaker Insertion
- Transthoracic Echocardiography (TTE)
- Transesophageal Echocardiography (TEE)
- Stress Echocardiography
- Heart Catheterization

This is in addition to cardiac studies that are currently part of our existing diagnostic imaging authorization program with NIA, including cardiac computed tomography angiographies (CCTA), multi-gated acquisition (MUGA) scans, and myocardial perfusion imaging (MPI)/nuclear stress tests.

About the program

The primary aim of the program is to promote the optimal use of diagnostic modalities in the assessment and treatment of cardiac diseases, with a focus on minimizing radiation exposure for patients through the use of the most efficient and least invasive testing options available. Program components include:

- Evidence-based clinical guidelines and proprietary algorithms to support clinically appropriate diagnostic options for each patient

- Consultations with cardiologists with expertise in elective cardiac diagnostic imaging and interventional procedures when peer-to-peer review is required

For complete details, please refer to [NIA's clinical guidelines](#) and the [Utilization Review Matrix](#) for coding information.

Requesting authorization and submitting claims

Ordering physicians may request authorization via the NIA website (www.RadMD.com) or by phone at 800-642-7543. NIA will begin accepting authorization requests on Dec. 18, 2018. Providers can check on the status of their authorization requests easily through www.RadMD.com (log in and select the “My Exams Requests” tab).

Please continue to send claims directly to Harvard Pilgrim as you do today (see the [Claims section of our StrideSM \(HMO\) Medicare Advantage Provider Manual](#)).

To ensure appropriate reimbursement, it is important that the rendering provider/facility confirms that authorization has been obtained prior to performing the procedure, as Harvard Pilgrim will deny payment if any of the above listed cardiac studies are performed without prior authorization. Members cannot be balance billed for such procedures.

Sign up for a webinar

NIA is offering educational webinars for providers who would like more information on this program and the authorization process:

- Tuesday, Dec. 4 at 8 a.m. and noon EST
- Wednesday, Dec. 5 at 8 a.m. and noon EST
- Tuesday, Dec. 11 at 8 a.m. and noon EST
- Wednesday, Dec. 12 at 8 a.m. and noon EST

To register for one of these sessions, please email NIASWebinar@magellanhealth.com at least one week prior, and include the name “Harvard Pilgrim,” as well as the webinar date, your group name, TIN, address, phone number, fax number, and number of participants attending.

Please refer to [this webinar flyer](#) for complete details on how to sign up for and log into one of these educational sessions.

Resources to assist you

For more information on this change, please refer to the following provider education materials:

- [Cardiac Program Checklist](#)
- [Cardiac Program Frequently Asked Questions](#) ◆

New Emergency Room Cost Sharing Structure for New Hampshire Plans

To help reduce emergency room (ER) overuse for the treatment of injuries and illnesses that aren't severe or life-threatening, Harvard Pilgrim is introducing a new member cost sharing structure for ER visits for our New Hampshire (NH) commercial plan members.

Currently, NH members pay the deductible and copayment for any ER visit. While that still applies for emergent conditions, starting on Jan. 1, 2019, NH plan members treated at an ER for non-emergent conditions are responsible for the deductible and 50% coinsurance after the deductible has been met. This change will apply for most, but not all, NH employer groups; members of commercial NH plans who are affected by this change will receive new ID cards with the updated cost sharing information.

Harvard Pilgrim will not deny ER claims due to this benefit change.

The new ER cost sharing structure applies for non-emergent diagnoses billed in the primary position and is relevant for diagnoses in approximately 25 categories, with the most common examples being:

- respiratory infections
- sprains and strains
- superficial injury; contusion
- ear conditions
- physical exam

Please refer to the [complete list of diagnosis codes](#) for which the higher ER copay would apply for additional information. ◆

Updates on Medical Drugs Obtained through Specialty Pharmacy

As you may know, Harvard Pilgrim Health Care makes select medical drugs available through both the buy and bill process and specialty pharmacy to allow members and providers greater choice and convenience. We will be making a few changes next year to ensure that member cost share is applied uniformly, no matter which method is used to obtain and bill for medical drugs.

After a review, we determined that, depending on which billing method was used, some commercial members were being charged an appropriate cost share for their medical drugs according to the terms of their policy and others were not. As of July 1, 2019, any commercial member receiving one of [these drugs](#) will be responsible for appropriate cost-sharing.

We are notifying members who take these medications of this change starting in November to allow them adequate time to plan for medical expenses and any reimbursement accounts. If any of your Harvard Pilgrim patients have questions about this change, please direct them to the member services phone number on the back of their Harvard Pilgrim ID card.

The change for providers is minimal. If you obtain medical drugs through buy and bill, the process remains the same as it is today. Likewise, it is also unchanged for medications you obtain through the specialty pharmacy that don't require prior authorization. However, if you would like to utilize the specialty pharmacy for medications on the attached list that do require prior authorization, beginning on July 1, 2019, please contact CVS Health-NovoLogix for prior authorization, rather than MedImpact.

We will be running a follow-up article next May as a reminder about this change. ◆

Billing Monitored Anesthesia Care Policy for Screening Colonoscopies for Commercial Members

Under our commercial Monitored Anesthesia Care (MAC) for Gastrointestinal Endoscopic Procedures policy, Harvard Pilgrim covers MAC for screening colonoscopies without cost sharing for members, in keeping with provisions of the Patient Protection and Affordable Care Act.

To ensure that these claims are processed correctly, it is important to bill MAC anesthesia for screening colonoscopies for commercial members with CPT code 00812 (Anesthesia for lower intestinal endoscopic procedures, endoscope introduced distal to duodenum; screening colonoscopy) regardless of findings — including in cases in which polyps are discovered and surgically removed.

Keep in mind that the MAC policy applies for CPT code 00811 (Anesthesia for lower intestinal endoscopic procedures, endoscopy introduced distal to duodenum; not otherwise specified), as well as combined upper and lower gastrointestinal procedures (00813) and upper gastrointestinal endoscopic procedures (00731 and 00732). For these codes, Harvard Pilgrim considers MAC for GI endoscopy medically necessary only when the policy criteria are met, and member cost sharing applies for MAC performed with colonoscopies that are not considered preventive screenings.

For more information, please refer to the updated [Monitored Anesthesia Care for Gastrointestinal Endoscopic Procedures Medical Policy](#). ◆

Billing Diagnosis Codes for Preventive Services

As you are aware, as a result of the Patient Protection and Affordable Care Act, Harvard Pilgrim requires that specific in-network preventive services be covered for members without cost sharing. Harvard Pilgrim would like to remind providers in our network that all diagnosis codes for preventive, screening, counseling, or wellness services should be billed in the primary position when indicated. Billing the appropriate diagnosis code in the primary position helps ensure that your claim will be accurately processed.

For more information regarding Harvard Pilgrim's coverage of preventive services and a detailed list of diagnosis codes, please refer to the [Patient Protection and Affordable Care Act \(Federal Health Care Reform\)](#) section of Harvard Pilgrim's commercial online *Provider Manual*. ♦

Newly Covered Codes for Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI)

In the May issue of *Network Matters*, Harvard Pilgrim announced that we created a new commercial medical policy for the management of SCODI, which includes confocal laser scanning ophthalmoscopy, scanning laser polarimetry, and optical coherence tomography.

Effective immediately, we are adding numerous codes to the list of covered ICD-10 diagnosis codes attached to the policy. This coding expansion includes, but is not limited to, the addition of diagnosis codes for retinal disorders such as macular degeneration and retinal neuropathy.

As a reminder, Harvard Pilgrim covers the following CPT codes only when they are submitted with a covered diagnosis code (the complete updated list of these codes is attached to the medical policy) and all the criteria indicated on the policy are met:

- 92132 – Scanning computerized ophthalmic diagnostic imaging, anterior segment, with interpretation and report, unilateral or bilateral
- 92133 – Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; optic nerve
- 92134 – Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina

Prior authorization is not required for coverage of SCODI. For complete information, please refer to Harvard Pilgrim's updated [Scanning Computerized Ophthalmic Diagnostic Imaging \(SCODI\) Medical Policy](#). ♦

Updates to Rituxan Medical Review Criteria

Harvard Pilgrim has updated our commercial medical review criteria for the medication Rituxan, which is covered with prior authorization for the medically necessary treatment of certain conditions in patients 18 and older.

It is no longer a requirement that a member have a hepatitis B screening with serologic assays documented in his or her chart or medical record to be covered for Rituxan. In addition, the drug is now covered for the following added indications, when all the necessary criteria on the policy are met:

- Moderate to severe pemphigus vulgaris
- Neuromyelitis optica (Devic disease)
- Refractory polymyositis or dermatomyositis (forms of idiopathic inflammatory myopathy)

As a reminder, prior authorization is required for Rituxan. To request authorization, please contact CVS Health–NovoLogix via phone (844-387-1435) or fax (844-851-0882).

For more information, refer to the updated [Rituxan Medical Review Criteria](#) and the appropriate prior authorization form on Harvard Pilgrim’s [Medical Drug Prior Authorization page](#). Also, please keep in mind that for any given drug, Harvard Pilgrim’s [Maximum Units Per Day Payment Policy](#) may apply. ◆

Generic Form of Makena Now Covered

Effective for dates of service beginning Nov. 1, 2018, Harvard Pilgrim has updated our prior authorization policy for Makena to also include coverage for the generic form of hydroxyprogesterone caproate. Makena and its generic version are indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.

The updated policy outlines the criteria that must be met for coverage of these medications. Please use HCPCS code J1729 (Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg) when billing for the generic version, and continue to use J1726 (Injection, hydroxyprogesterone caproate, [Makena], 10 mg) for brand-name Makena.

To request authorization, please contact CVS Health–NovoLogix via phone (844-387-1435) or fax (844-851-0882).

For more information, refer to the updated [Makena Medical Review Criteria](#) and the appropriate prior authorization form on Harvard Pilgrim's [Medical Drug Prior Authorization page](#). Also, please keep in mind that for any given drug, Harvard Pilgrim's [Maximum Units Per Day Payment Policy](#) may apply. ◆

Diabetes Prevention and Management Programs and Resources

As November is American Diabetes Month, Harvard Pilgrim wants to remind you of our commitment to the prevention and management of diabetes in members. Our programs often include close collaboration between the member, a Harvard Pilgrim-certified personal health coach or nurse care manager, and the member's primary care physician (PCP).

Diabetes prevention

Harvard Pilgrim has wellness programs designed to promote healthy lifestyles, helping members reduce their risk factors for conditions like diabetes in a variety of ways. Our [Lifestyle Management Program](#) supports members in maintaining general wellness by offering information, tools and resources needed to implement and maintain a healthy lifestyle. The approach includes, among other things:

- telephonic support in which a dedicated team of certified health coaches/nurse educators work with members and their families to help them make informed decisions about lifestyle opportunities like nutrition management, physical activity, and weight management
- online wellness resources like self-paced educational workshops, fitness logs, and trackers that sync with more than 80 personal tracking devices, as well as recipes and a meal planner

To get a personal health coach, members simply sign on to *HPHConnect* and indicate on the confidential health questionnaire that they would like to work with a coach.

Diabetes management

[Harvard Pilgrim's Diabetes Management Program](#) provides support, clinical resources, and educational materials for our members who have been diagnosed with diabetes, as well as the physicians who treat them. Members with diabetes receive a Diabetes Care Report explaining the importance of diabetes testing — for example, dilated eye exam to detect retinopathy, cholesterol test to detect hyperlipidemia, HbA1c test for hyperglycemia, and urinalysis for nephropathy. PCPs regularly receive registries containing patient-specific information, as well, including a Diabetes Gap in Care Summary to assist with monitoring and outreach efforts, and multiple prescriber reports to help coordinate care, avoid drug duplication, and monitor medication adherence.

Members who are at moderate or higher risk are additionally referred to our [High-Risk Diabetes Program](#) and receive outreach and personalized care from a Harvard Pilgrim nurse care manager. Close interaction with the member's PCP and relevant specialists is also an important component of the care manager's role. To refer a patient for diabetes nurse care management services, call 1-866-750-2068. The U.S. Department of Health and Human Services offers [this helpful toolbox](#) for providers. ♦

New Pharmacy Prior Authorizations for 2019

Effective Jan. 1, 2019, Harvard Pilgrim will require prior authorization for coverage of attention deficit hyperactivity disorder (ADHD) medications, antineoplastic medications, and medications used to treat pulmonary arterial hypertension for members of our commercial plans. We are creating new pharmacy prior authorization clinical guidelines for these categories of medications, which will outline the criteria that must be met for coverage and serve as a tool to promote quality, safety, and cost-effective pharmacotherapy.

These new prior authorization requirements will apply only to patients being newly prescribed these medications; patients who are currently taking these medications today will be able to continue being prescribed them without a prior authorization.

The criteria required for prior authorization of ADHD medications, antineoplastic medications, and pulmonary arterial hypertension medications will include, but not be limited to:

ADHD medications:

- The prescriber must ensure that ADHD is the appropriate diagnosis.
- If the request is for a multi-source brand, the patient is required to have first tried and failed a sufficient course of therapy with the generic version of the requested medication and at least two alternative formulary medications.

Antineoplastic medications:

- The patient must have a confirmed diagnosis of one of the FDA-approved or National Comprehensive Cancer Network (NCCN)-recognized indications.

Pulmonary arterial hypertension medications:

- The prescriber must ensure the appropriate utilization of the medication indicated for pulmonary arterial hypertension based on FDA-approved indications and appropriate clinical criteria.

The complete coverage criteria for these medications will be detailed in the prior authorization guidelines that will be posted in the [Pharmacy section](#) of Harvard Pilgrim’s website by Jan. 1, 2019, along with the appropriate Medication Request Forms.

Please keep the following in mind when making an authorization request: The drug-specific clinical criteria that Harvard Pilgrim makes available to providers contains in-depth information that is not always explicitly detailed in the standard medication request forms. To expedite your authorization request and help ensure it can be evaluated properly, it is important to review the criteria for the drug you are requesting coverage for and include any information outlined in the criteria on your pharmacy medication request form. ◆

Pharmacy and Therapeutics Committee Meeting Update

At the September 17, 2018 meeting, the Harvard Pilgrim Pharmacy & Therapeutics Committee reviewed the medications below and decided the following:

P&T Committee Review and Decisions		
Name	Indication	Decision
Arnuity Ellipta (fluticasone furoate)	Used to control and prevent asthma for patients aged 5 years and older.	<ul style="list-style-type: none"> • Premium and Value formularies: Moved to preferred brand • Medicare Advantage Formulary: Remains non-formulary
Stiolto Respimat (tiotropium bromide, olodaterol)	Used to treat airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).	<ul style="list-style-type: none"> • Premium and Value formularies: Moved to preferred brand • Medicare Advantage Formulary: Continued coverage at Tier 3

<p>Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide [TAF])</p>	<p>Used to treat HIV-1 in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed.</p>	<ul style="list-style-type: none"> • Premium and Value formularies: Moved to preferred brand • Medicare Advantage Formulary: Continued coverage at Tier 5
<p>Genvoya (elvitegravir, cobicistat, emtricitabine, TAF)</p>	<p>Used to treat HIV-1 infection in adults and pediatric patients.</p>	<ul style="list-style-type: none"> • Premium and Value formularies: Moved to preferred brand • Medicare Advantage Formulary: Continued coverage at Tier 5
<p>Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate TDF)</p>	<p>Used to treat HIV-1 infection in adults and pediatric patients 12 years of age and older.</p>	<ul style="list-style-type: none"> • Premium and Value formularies: Moved to preferred brand • Medicare Advantage Formulary: Continued coverage at Tier 5
<p>Descovy (emtricitabine, TAF)</p>	<p>Used in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients.</p>	<ul style="list-style-type: none"> • Premium and Value formularies: Moved to preferred brand • Medicare Advantage Formulary: Continued coverage at Tier 5
<p>Juluca (dolutegravir, rilpivirine)</p>	<p>Used to treat HIV-1 infection in adult patients.</p>	<ul style="list-style-type: none"> • Premium and Value formularies: Moved to preferred brand • Medicare Advantage Formulary: Continued coverage at Tier 5

Symfi/Symfi Lo (efavirenz, lamivudine, TDF)	Used to treat HIV-1 infection in adult and pediatric patients.	<ul style="list-style-type: none"> • Premium and Value formularies: Moved to preferred brand • Medicare Advantage Formulary: Continued coverage at Tier 5
Cimduo (Lamivudine, TDF)	Used in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult and pediatric patients.	<ul style="list-style-type: none"> • Premium and Value formularies: Moved to preferred brand • Medicare Advantage Formulary: Continued coverage at Tier 5

OFFICE ASSISTANT

Update to Reimbursement Process for Observation to Inpatient Transition

Harvard Pilgrim has updated the commercial reimbursement process for observation stay and inpatient admissions for facilities reimbursed via the percent-of-charge methodology, in an effort to improve efficiency and simplify the administrative experience for these providers.

Facilities reimbursed on a percent-of-charge basis no longer need to appeal the denial of observation services provided prior to midnight in order to receive payment for observation stays that transition to inpatient admissions. Instead, Harvard Pilgrim will determine the hours that count as observation and those considered inpatient and provide the appropriate separate reimbursement up front.

Harvard Pilgrim’s Observation Stay Payment Policy states that for an observation stay that converts to an inpatient stay after midnight, percent-of-charge-based reimbursement for the observation stay is not considered to be included in the inpatient reimbursement, and the observation bed charge for the time prior to the date of the inpatient admission is separately reimbursed.

How is the process changing?

Harvard Pilgrim's definition of observation stay versus inpatient care is not changing, and the reimbursement amount these facilities ultimately receive will be the same. However, in the past, payment for the observation stay portion of this care would have initially been denied and the facility would have had to submit an appeal to receive the correct payment.

Going forward, Harvard Pilgrim is eliminating the administrative burden of this extra step to ensure more timely payment. We will determine the observation hours prior to the day of admission by subtracting the admission hour submitted from the total submitted observation hours, and calculate the proper reimbursement based on the provider's contractual agreement.

More information

Keep in mind that separate reimbursement for observation stay applies only to the hours prior to midnight. For example, if a patient is in observation status starting at 7 p.m. on Dec. 1 and admitted to inpatient care at 10 a.m. on Dec. 2, the observation care ceases to be counted as observation time at 11:59 p.m. on Dec. 1. The care delivered between 7 p.m. and 11:59 p.m. are separately reimbursed as observation care, but the hours spent between midnight and 9:59 a.m. on Dec. 2 are included in the inpatient reimbursement and not separately reimbursed as observation time.

For more information, please refer to Harvard Pilgrim's updated [Observation Stay Payment Policy](#). ♦

Modifier SA for Reporting on Behalf of Non-Physician Practitioners

Harvard Pilgrim is updating our commercial claims submission requirements for contracted physicians reporting services on behalf of non-physician practitioners who are not contracted with Harvard Pilgrim.

For commercial claims with dates of service beginning Jan. 1, 2019, when a Harvard Pilgrim-contracted physician is reporting on behalf of a nurse practitioner, physician assistant, or clinical nurse specialist who is not contracted with Harvard Pilgrim, the physician will be required to document this by appending modifier SA to the claim. Additionally, the NPI of the supervising physician will need to be documented in field 24J on the CMS-1500 claim form or its electronic equivalent. Modifier SA should not be appended to a claim for a service provided by a non-physician practitioner who is contracted directly with Harvard Pilgrim.

While the inclusion of modifier SA will be required to indicate that the physician is documenting the care on behalf of a non-physician practitioner, appending this modifier

to the claim will not have any effect on reimbursement. For more information, please refer to Harvard Pilgrim's updated [Certified Nurse Midwives, Certified Professional Midwives, Nurse Practitioners, and Physician Assistants Payment Policy](#). ♦

***Network Matters* is a monthly newsletter for the Harvard Pilgrim provider network**

Robert Farias, Senior Vice President, Corporate Network Strategy

Annmarie Dadoly, Editor

Joseph O'Riordan, Writer

Kristin Edmonston, Production Coordinator

Read *Network Matters* online at www.hphc.org/providers. For questions or comments about *Network Matters*, contact Annmarie Dadoly at annmarie_dadoly@harvardpilgrim.org or (617) 509-8074.